Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SHE:000766)
China · Delayed Price · Currency is CNY 16.47
+0.08 (0.49%)
Sep 4, 2026, 3:04 PM CST
SHE:000766 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 15,918 | 26,569 | 15,174 | 19,272 | 5,093 | 4,591 | |
Market Cap Growth | -29.16% | 75.10% | -21.26% | 278.37% | 10.95% | 45.71% |
Enterprise Value | 17,451 | 28,104 | 16,698 | 20,787 | 6,665 | 6,230 |
Last Close Price | 16.47 | 27.49 | 15.70 | 19.94 | 5.27 | 4.75 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 647.42 | 774.91 | 268.86 | 438.66 | 168.93 | 130.15 |
Forward PE | - | 15.74 | 15.74 | 15.74 | 15.74 | 15.74 |
PS Ratio | 14.78 | 22.71 | 11.47 | 13.08 | 3.46 | 3.03 |
PB Ratio | 6.87 | 11.50 | 6.73 | 8.31 | 2.15 | 1.96 |
P/TBV Ratio | 8.27 | 12.43 | 7.34 | 9.12 | 2.40 | 2.22 |
P/FCF Ratio | 576.05 | 648.21 | 133.60 | 223.80 | 29.20 | 40.68 |
P/OCF Ratio | 190.49 | 252.91 | 93.24 | 170.88 | 25.70 | 33.19 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 16.20 | 24.02 | 12.63 | 14.11 | 4.53 | 4.11 |
EV/EBITDA Ratio | 107.67 | 160.02 | 81.46 | 105.79 | 34.61 | 34.10 |
EV/EBIT Ratio | 172.89 | 245.41 | 118.94 | 170.73 | 55.11 | 54.98 |
EV/FCF Ratio | 631.52 | 685.65 | 147.02 | 241.40 | 38.21 | 55.21 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.87 | 0.79 | 0.80 | 0.73 | 0.76 | 0.79 |
Debt / EBITDA Ratio | 12.48 | 10.27 | 8.69 | 8.66 | 9.34 | 10.14 |
Debt / FCF Ratio | 73.17 | 44.28 | 15.87 | 19.77 | 10.31 | 16.42 |
Net Debt / Equity Ratio | 0.66 | 0.67 | 0.68 | 0.66 | 0.62 | 0.66 |
Net Debt / EBITDA Ratio | 9.47 | 8.78 | 7.45 | 7.76 | 7.59 | 8.49 |
Net Debt / FCF Ratio | 55.48 | 37.62 | 13.45 | 17.70 | 8.38 | 13.74 |
Asset Turnover | 0.23 | 0.26 | 0.29 | 0.32 | 0.32 | 0.32 |
Inventory Turnover | 0.82 | 0.87 | 0.88 | 1.02 | 0.92 | 0.85 |
Quick Ratio | 1.46 | 1.58 | 0.38 | 1.28 | 1.25 | 0.38 |
Current Ratio | 1.95 | 2.33 | 0.56 | 1.94 | 1.84 | 0.57 |
Return on Equity (ROE) | 1.06% | 1.50% | 2.45% | 1.85% | 1.24% | 1.46% |
Return on Assets (ROA) | 1.36% | 1.60% | 1.95% | 1.65% | 1.62% | 1.47% |
Return on Invested Capital (ROIC) | 2.13% | 2.40% | 3.07% | 2.50% | 1.82% | 1.66% |
Return on Capital Employed (ROCE) | 2.50% | 2.90% | 6.00% | 3.10% | 3.00% | 4.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.15% | 0.13% | 0.37% | 0.23% | 0.59% | 0.77% |
FCF Yield | 0.17% | 0.15% | 0.75% | 0.45% | 3.42% | 2.46% |
Payout Ratio | 338.18% | 237.16% | 150.57% | 189.66% | 293.85% | 276.41% |
Buyback Yield / Dilution | 9.14% | 8.87% | -7.05% | 12.57% | -13.97% | 9.24% |